Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shell lifts production guidance for first quarter

(Sharecast News) - Oil and gas titan Shell has raised its short-term production forecasts and said it expects an increase in margins as it updated its guidance for the first quarter on Friday.

Integrated gas production is now tipped to come it at 960-1,000 thousand barrels of oil equivalents per day (kboe/d), up from February's guidance of 930-990 kboe/d, while the upstream production guidance range has been narrowed to 1,820-1,920 kboe/d from 1,730-1,930 kboe/d previously.

Meanwhile, increased forecasts for utilisation - the actual usage of refineries and chemical plants as a percentage of the rated capacity - mean that indicative refining margins are expected to be $12 a barrel in the first quarter, up from $10 in the fourth, while indicative chemicals margins should grow to $151/tonne from $125/tonne.

Within the integrated gas division, Shell said that trading and optimisation results are expected to be "strong, but significantly lower than an exceptional Q4'23".

In upstream, it revealed it would take an exploration well write-off of around $600m, mainly as a result of operations in Albania.

Share this article

Related Sharecast Articles

UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
Somero trading in line with expectations
(Sharecast News) - Somero Enterprises said in an update on Monday that trading for the first five months of 2024 was consistent with expectations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.